TCT 2025: One-Year ENCIRCLE Trial Outcomes
The Medical Dialogues Bureau at the TCT Conference 2025 in San Francisco, USA, reports on the outcomes of the ENCIRCLE trial.
Percutaneous transseptal mitral valve replacement (TMVR) with the SAPIEN M3 System significantly reduced mitral regurgitation (MR) severity, improved functional status and quality of life, and achieved low mortality and heart failure hospitalization rates at one year.
According to results presented by Dr. John Webb on behalf of the ENCIRCLE investigators at TCT 2025, the trial demonstrated positive outcomes for patients with symptomatic MR who are not suitable candidates for surgery or other commercially available transcatheter treatment options.
The ENCIRCLE trial is the first pivotal study to evaluate outcomes of a fully percutaneous, transseptal TMVR system.
Author's summary: TCT 2025 presents ENCIRCLE trial results.
More News
- Who controls the National Guard: An explainer
- Horoscopes Oct. 29, 2025: Gabrielle Union, it’s time to put yourself first.
- ChatGPT teams up with PayPal to make it easier for you to buy stuff in chat
- 7 basic science discoveries that changed the world
- Top batters dismissed for zero as Zimbabwe suffer disappointing T-20 loss to Afghanistan – Nehanda Radio
- From MRI to Ozempic: breakthroughs that show why fundamental research must be protected
- COLUMN: What next for Welshpool’s Air Ambulance Base?
- The ECHR: legal and political fault lines
- Etsy names former head of Depop, Kruti Patel Goyal, as its new CEO | TechCrunch
- Chatham merchants welcome community hub, mall revitalization projects